Adverse events60

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 60

Type	Event	Organ system	Group	Affected	At risk
other	Decreased appetite	Metabolism and nutrition disorders	All d-ATS Treatment During the Dose-Optimization Phase	64	110
other	Decreased appetite	Metabolism and nutrition disorders	d-ATS Patch Treated Arm During the Double Blind Phase	13	106
other	Decreased appetite	Metabolism and nutrition disorders	Placebo Treated Arm During the Double Blind Phase	2	106
other	Hyperkalemia	Metabolism and nutrition disorders	All d-ATS Treatment During the Dose-Optimization Phase	9	110
other	Hyperkalemia	Metabolism and nutrition disorders	d-ATS Patch Treated Arm During the Double Blind Phase	4	106
other	Hyperkalemia	Metabolism and nutrition disorders	Placebo Treated Arm During the Double Blind Phase	5	106
other	Insomnia	Psychiatric disorders	All d-ATS Treatment During the Dose-Optimization Phase	29	110
other	Insomnia	Psychiatric disorders	d-ATS Patch Treated Arm During the Double Blind Phase	6	106
other	Insomnia	Psychiatric disorders	Placebo Treated Arm During the Double Blind Phase	5	106
other	Affect lability	Psychiatric disorders	All d-ATS Treatment During the Dose-Optimization Phase	14	110
other	Affect lability	Psychiatric disorders	d-ATS Patch Treated Arm During the Double Blind Phase	3	106
other	Affect lability	Psychiatric disorders	Placebo Treated Arm During the Double Blind Phase	0	106
other	Initial insomnia	Psychiatric disorders	All d-ATS Treatment During the Dose-Optimization Phase	10	110
other	Initial insomnia	Psychiatric disorders	d-ATS Patch Treated Arm During the Double Blind Phase	1	106
other	Initial insomnia	Psychiatric disorders	Placebo Treated Arm During the Double Blind Phase	0	106
other	Irritability	General disorders	All d-ATS Treatment During the Dose-Optimization Phase	21	110
other	Irritability	General disorders	d-ATS Patch Treated Arm During the Double Blind Phase	2	106
other	Irritability	General disorders	Placebo Treated Arm During the Double Blind Phase	1	106
other	Application site pain	General disorders	All d-ATS Treatment During the Dose-Optimization Phase	12	110
other	Application site pain	General disorders	d-ATS Patch Treated Arm During the Double Blind Phase	0	106

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01711021/events

API reference For AI assistants

Adverse events60

Sources 3

Read this list from software.